Abstract
Recent advances in migraine therapy include the recognition of analgesic or ergotamine abuse as a cause of chronic daily migraine, the introduction of effective non-narcotic drugs such as chlorpromazine, dihydroergotamine and corticosteroids for the treatment of intractable migraine attacks, the increased number of beta-blockers now recognized as effective prophylactic agents and the introduction of calcium-channel blockers for prophylaxis. There is a sufficient variety of antimigraine drugs, and therapy should be successful for most sufferers.
MeSH terms
-
Acute Disease
-
Adrenal Cortex Hormones / therapeutic use
-
Adrenergic beta-Antagonists / therapeutic use
-
Analgesics / therapeutic use
-
Calcium Channel Blockers / therapeutic use
-
Chlorpromazine / therapeutic use
-
Dihydroergotamine / therapeutic use
-
Ergotamine / therapeutic use
-
Humans
-
Methysergide / therapeutic use
-
Migraine Disorders / drug therapy*
-
Migraine Disorders / prevention & control
-
Narcotics / therapeutic use
-
Pizotyline / therapeutic use
Substances
-
Adrenal Cortex Hormones
-
Adrenergic beta-Antagonists
-
Analgesics
-
Calcium Channel Blockers
-
Narcotics
-
Pizotyline
-
Dihydroergotamine
-
Ergotamine
-
Chlorpromazine
-
Methysergide